Bausch + Lomb names chief medical officer
ROCHESTER, N.Y. — Bausch + Lomb on Friday appointed a clinical professor of ophthalmology to serve as the company’s first-ever chief medical officer.
As CMO, Calvin Roberts will coordinate B + L’s research and development efforts across its vision care, pharmaceuticals and surgical business units.
In addition to his role at Bausch + Lomb, Roberts is a clinical professor of ophthalmology at Weill Medical College of Cornell University. He also is a member of the board of directors at Alimera Sciences, a biopharmaceutical company he co-founded in 2003.
“I look forward to bringing the perspective of clinical optometrists and ophthalmologists to the development of new, innovative products to benefit our patients,” Roberts said. “Bausch + Lomb has a history of great science and great scientists, and working together we can best serve the needs of our customers and patients.”
NAD reviews Exergen’s ad claims for temporal thermometers
NEW YORK — The National Advertising Division of the Council of Better Business Bureaus on Thursday recommended that Exergen modify superior performance claims for its temporal thermometers as compared with tympanic (in-the-ear) readings.
The NAD, the advertising industry’s self-regulatory forum, reviewed print and Internet advertising claims made by Exergen following a challenge by Kaz USA, the maker of Braun ear thermometers. Exergen explained to the NAD that temporal thermometry is the newest form of noninvasive temperature measurement, measuring temperature on the skin’s surface of the temporal artery when it is swept across the forehead. The advertiser asserted that the technology has been widely recognized as accurate.
The NAD noted in its decision that many of the studies, which relied upon by the advertiser to support its claims, failed to test the most recent generation of ear thermometry and compared temporal artery thermometers to oral, rectal or other thermometers. While such studies might support other performance claims for the advertiser’s temporal thermometer, they are insufficient to provide direct support for the advertiser’s superior accuracy claims regarding ear thermometers, the NAD said.
The NAD recommended that Exergen modify its claims to clearly and conspicuously disclose that the comparison being made is with cold-tip ear thermometry, since Kaz markets a tympanic thermometer featuring a patented pre-warmed tip.
Exergen, in its advertiser’s statement, said that it disagrees “with [the] NAD that there is any need to modify our superiority claims. However, in the spirit of cooperation with the self-regulatory process, we will take [the] NAD’s recommendations into account in future advertising.”
NAD recommends modification of Peak Life’s ad claims
NEW YORK — The National Advertising Division of the Council of Better Business Bureaus on Thursday recommended that Peak Life modify its advertising to clearly convey the message that claimed sleep benefits associated with its Somnapure dietary supplement are achieved from a regular, consistent program of supplementation with these ingredients, and not with one-time use.
The NAD also found that Peak Life failed to make clear that visitors to its website are viewing advertising and not third-party, independently generated health news, and failed to adequately disclose that the site is owned and operated by the advertiser itself.
The NAD recommended that the advertiser take further steps to clearly and conspicuously disclose these material connections. The company, in its advertiser’s statement, said it would “make appropriate adjustments to the format and presentation of certain claims consistent with the NAD’s recommendations.”
The NAD, the advertising industry’s self-regulatory forum, reviewed advertising for the product as part of its ongoing monitoring program and in conjunction with its initiative with the Council for Responsible Nutrition to expand its review of dietary supplement claims.